How pharma marketing needs to adapt as community pharmacies take centre stage

August 28, 2025
Business Services, Medical Communications, Sales and Marketing 10 Year Health Plan, Pharmacy, m3, pharmacy

The UK governmentโ€™s 10-Year Health Plan is moving pharmacists to the frontline of primary care For decades, community pharmacies were …

European Commission approves HIV prevention injection

August 28, 2025
Medical Communications, Research and Development European Commission, Gilead Science, HIV, HIV/AIDS, US Food and Drug Administration, World Health Organisation

The European Commission (EC) has granted marketing authorisation for Gilead Scienceโ€™s Yeytuo (lenacapavir), the first twice-yearly injectable medicine approved in …

EMA grants orphan drug designation for Rocaโ€™s treatment of radiation maculopathy

August 28, 2025
Medical Communications, Research and Development European Medicines Agency (EMA), Oncology, Opthalmology, Roca Therapeutics, maculopathy

The European Medicines Agency (EMA) has granted Orphan Drug Designation to Roca Therapeutics for its lead candidate RCT002, marking the …

The UK’s Life Sciences Sector Plan: a fresh launchpad or a continued labyrinth for the uptake of innovative medicines?

August 27, 2025
Business Services, Market Access, Market Access Consultancy, Sales and Marketing NHS, Visions4Health

As the UK healthcare system navigates a period of significant change, the path to successful market access is becoming increasingly …

handshake-2056023_960_720

Terumo to acquire Oxford spin-out OrganOx in $1.5b deal

August 26, 2025
Mergers and Acquisitions Corporate, OrganOx, Terumo, University of Oxford, organ transplantation

Japanese medical technology company Terumo has announced it will acquire OrganOx, a University of Oxford, UK, spin-out specialising in organ …

Neogap Therapeutics appoints Jonas Mattson to its board of directors

August 26, 2025
Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors

Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …

hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

August 22, 2025
Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …

johnsonsss

Johnson & Johnson commits $2bn to new manufacturing facility in North Carolina, US

August 22, 2025
Manufacturing and Production Corporate, Fujifilm, Johnson & Johnson

Johnson & Johnson has announced a $2bn investment in a new manufacturing facility in Holly Springs, North Carolina, US, expanding …

epilepsy-623346_960_720

Epilepsy Research Institute opens 2025-26 grant round with new awards

August 21, 2025
Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research

The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …

Global study calls for overhaul of hepatitis B care to meet WHO targets

August 21, 2025
Medical Communications, Medical/ Scientific Writing Hepatology, World Health Organisation, hepatitis B, liver damage, medical study

A major global study has warned that current models of hepatitis B care are failing patients and could jeopardise the …

Five Facts about epilepsy

August 21, 2025
Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures

1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …

Single national formulary and community care: a closer look at the 10-Year Health Plan

August 21, 2025
Business Services, Market Access Gateway to Local Adoption, NHS, Visions4Health

In the fourth of the Gateway to Local Adoption series, Visions4Health caught up with Frances Smith, Clinical Pharmacy Services Manager, …

HUTCHMED completes enrolment in phase 3 trial for lung cancer

August 21, 2025
Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …

Christopher Conway joins BioDuro board to strengthen global leadership

August 21, 2025
Contract Manufacturing, Manufacturing and Production Bio X Cell, BioDuro, Corporate, board of directors, contract research development and manufacturing organisation

BioDuro has announced the appointment of Christopher Conway, CEO of Bio X Cell, to its board of directors, effective immediately. …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation

August 19, 2025
Mergers and Acquisitions, Research and Development BioMed X, Novo Nordisk, Pharmacy, drug development, therapeutic peptides

BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of therapeutic peptides โ€“ a major …

partnership

IQVIA and Veeva agree long-term partnerships to support service delivery

August 19, 2025
Mergers and Acquisitions Corporate, IQVIA, Veeva Systems

IQVIA and Veeva Systems have announced the formation of global partnerships covering clinical and commercial services. IQVIA provides advanced analytics, …

Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

August 18, 2025
Business Services, Research and Development Ease Healthcare, Hawkeye Bio, HydroGraph, Oncology, lung cancer

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and Ease Healthcare to support the …

money-2180330_960_720

Anocca secures ยฃ32m to advance pancreatic cancer trial

August 18, 2025
Research and Development Anocca, Oncology, Pancreatic cancer, research funding

Swedish biopharma Anocca has raised approximately ยฃ32m (SEK 440m) to support the early-stage clinical development of VIDAR-1, its lead TCR-T …

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

FDA decision on Neurizonโ€™s ALS therapy delayed until October

August 18, 2025
Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis

Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the companyโ€™s Clinical …

FDA approves first new fibromyalgia therapy in over 15 years

August 18, 2025
Medical Communications, Research and Development Pain, Tonix Pharmaceutical, US Food and Drug Administration, chronic pain, clinical trial, fibromyalgia

The US Food and Drug Administration (FDA) has approved Tonix Pharmaceuticalโ€™s Tonmya (cyclobenzaprine hydrochloric acid) for the treatment of fibromyalgia …

The Gateway to Local Adoption Series

Latest content